Yao, Japan

Keizo Kinashi


Average Co-Inventor Count = 3.5

ph-index = 2

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 1981-1985

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Keizo Kinashi: Innovator in Antihypertensive Compounds

Introduction

Keizo Kinashi is a notable inventor based in Yao, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antihypertensive agents. With a total of 3 patents to his name, Kinashi's work has had a meaningful impact on medical science.

Latest Patents

Kinashi's latest patents include innovative compounds that serve as hypotensive agents. One of his notable inventions is a novel 2-oxo-imidazolidine derivative, which is characterized by the formula: ##STR1##. In this formula, R.sup.1 represents lower alkyl or phenyl-lower alkyl, R.sup.2 is lower alkyl, R.sup.3 is an alkyl chain of one to twelve carbon atoms or phenyl-lower alkyl, and R.sup.4 is either hydrogen or lower alkyl. These compounds and their pharmaceutically acceptable salts are disclosed as useful hypotensive agents. Another significant patent involves a 2-oxoimidazolidine derivative, which is also useful as a hypotensive agent, showcasing the versatility and importance of his research.

Career Highlights

Kinashi is currently associated with Tanabe Seiyaku Company, Limited, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing treatments for hypertension, contributing to better health outcomes for patients.

Collaborations

Throughout his career, Kinashi has collaborated with esteemed colleagues such as Naoto Yoneda and Jyoji Kato. These partnerships have fostered a collaborative environment that enhances the quality and scope of their research.

Conclusion

Keizo Kinashi's contributions to the field of antihypertensive compounds exemplify the importance of innovation in pharmaceuticals. His patents reflect a commitment to improving health through scientific advancement.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…